Visus CEO updates on lead product candidate, 2021 pipeline

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

Related Videos

Related Content

Advertisement

March 17th 2025

Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

February 24th 2025

Cleveland Clinic’s Cole Eye Institute expands with Jeffrey and Patricia Cole Pavilion

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

February 15th 2025

Envision Summit 2025: Importance of comanagement in glaucoma treatment

February 15th 2025

MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma

Related Content

Advertisement

March 17th 2025

Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

February 24th 2025

Cleveland Clinic’s Cole Eye Institute expands with Jeffrey and Patricia Cole Pavilion

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

February 15th 2025

Envision Summit 2025: Importance of comanagement in glaucoma treatment

February 15th 2025

MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma